553 related articles for article (PubMed ID: 19561477)
21. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
[TBL] [Abstract][Full Text] [Related]
23. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Takamori H; Kanemitsu K; Hirota M; Ikeda O; Tanaka H; Beppu T; Yamashita Y; Oya N; Baba H
Ann Surg Oncol; 2011 Apr; 18(4):1110-5. PubMed ID: 21046268
[TBL] [Abstract][Full Text] [Related]
24. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
Talamonti MS; Small W; Mulcahy MF; Wayne JD; Attaluri V; Colletti LM; Zalupski MM; Hoffman JP; Freedman GM; Kinsella TJ; Philip PA; McGinn CJ
Ann Surg Oncol; 2006 Feb; 13(2):150-8. PubMed ID: 16418882
[TBL] [Abstract][Full Text] [Related]
25. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
26. [Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas].
Ishikawa O; Ohigashi H; Sasaki Y; Furukawa H; Kabuto T; Imaoka S; Iwanaga T; Nakaizumi A; Uehara H; Matayoshi Y
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1635-41. PubMed ID: 8886033
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
Lind PA; Isaksson B; Almström M; Johnsson A; Albiin N; Byström P; Permert J
Acta Oncol; 2008; 47(3):413-20. PubMed ID: 17882555
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191
[TBL] [Abstract][Full Text] [Related]
30. Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma.
Mattiucci GC; Ippolito E; D'Agostino GR; Alfieri S; Antinori A; Crucitti A; Balducci M; Deodato F; Luzi S; Macchia G; Smaniotto D; Morganti AG; Valentini V
Ann Surg Oncol; 2013 Feb; 20(2):423-9. PubMed ID: 23208130
[TBL] [Abstract][Full Text] [Related]
31. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
[TBL] [Abstract][Full Text] [Related]
32. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Satoi S; Toyokawa H; Yanagimoto H; Yamamoto T; Kamata M; Ohe C; Sakaida N; Uemura Y; Kitade H; Tanigawa N; Inoue K; Matsui Y; Kwon AH
J Gastrointest Surg; 2012 Apr; 16(4):784-92. PubMed ID: 22160780
[TBL] [Abstract][Full Text] [Related]
33. Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Kurosaki I; Kawachi Y; Nihei K; Tsuchiya Y; Aono T; Yokoyama N; Shimizu T; Hatakeyama K
Pancreas; 2009 Mar; 38(2):161-7. PubMed ID: 18797423
[TBL] [Abstract][Full Text] [Related]
34. The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
Regine WF; John WJ; McGrath P; Strodel WE; Mohiuddin M
J Hepatobiliary Pancreat Surg; 2000; 7(1):53-7. PubMed ID: 10982592
[TBL] [Abstract][Full Text] [Related]
35. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
36. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
[TBL] [Abstract][Full Text] [Related]
37. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
Murphy JD; Adusumilli S; Griffith KA; Ray ME; Zalupski MM; Lawrence TS; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):801-8. PubMed ID: 17379445
[TBL] [Abstract][Full Text] [Related]
38. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
[TBL] [Abstract][Full Text] [Related]
40. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
Iott MJ; Corsini MM; Miller RC
Clin J Oncol Nurs; 2008 Aug; 12(4):599-605. PubMed ID: 18676327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
